SOLID TUMORS HARBORING A TP53 Y220C MUTATION

Clinical trials for SOLID TUMORS HARBORING A TP53 Y220C MUTATION explained in plain language.

Never miss a new study

Get alerted when new SOLID TUMORS HARBORING A TP53 Y220C MUTATION trials appear

Sign up with your email to follow new studies for SOLID TUMORS HARBORING A TP53 Y220C MUTATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

First-in-Human trial launches for new targeted cancer pill

Disease control Recruiting now

This is the first study in people to test a new oral drug called GenSci128. It aims to see if the drug is safe and tolerable for patients with advanced solid tumors that have a specific genetic mutation called TP53 Y220C. The study will also look at how the drug moves through the…

Matched conditions: SOLID TUMORS HARBORING A TP53 Y220C MUTATION

Phase: PHASE1 • Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. • Aim: Disease control

Last updated Mar 03, 2026 14:06 UTC

SOLID TUMORS HARBORING A TP53 Y220C MUTATION

Get alerted when new SOLID TUMORS HARBORING A TP53 Y220C MUTATION trials appear

First-in-Human trial launches for new targeted cancer pill